Retinal implant

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

Retrieved on: 
Wednesday, October 12, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005068/en/
    Max Strus, American professional basketball player, practices his on-court skills with sharper vision from EVO ICL - a new FDA-approved vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, Strus had EVO lenses implanted by his doctor to upgrade his vision and break free from the hassles of eyeglasses and contact lenses.
  • Following the EVO procedure, he went from struggling with the hassles of contact lenses, both on and off the court, to having clear vision better than 20/20.
  • Starting this month, Max Strus will share his journey in national and social media campaigns which will later be expanded globally.

STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems

Retrieved on: 
Wednesday, August 10, 2022

Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.

Key Points: 
  • Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.
  • He decided to undergo the EVO procedure, which involved adding a small, flexible lens in both eyes to correct his distance vision.
  • Joe Jonas was a great candidate for EVO and we are thrilled to have helped him achieve his vision goals.
  • Joe Jonas needed EVO lenses below -5.0 diopters, so he was a great candidate for EVO, said Scott D. Barnes, MD, Chief Medical Officer of STAAR Surgical.

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells

Retrieved on: 
Tuesday, June 1, 2021

OpRegen is an allogeneic retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA), or dry (atrophic) AMD.

Key Points: 
  • OpRegen is an allogeneic retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of age-related macular degeneration (AMD) with geographic atrophy (GA), or dry (atrophic) AMD.
  • These findings suggest integration of the new RPE cells with functional photoreceptors in areas that previously showed no presence of any of these cells.
  • After reporting the first case of retinal restoration last year, it is extremely exciting for me to see retinal restoration replicated in additional OpRegen-treated patients.
  • Nearly all cases of wet AMD eventually will develop the underlying atrophic AMD if the newly formed blood vessels are treated correctly.

Eyedaptic unveils EYE3, the premier version of its augmented reality glasses for age-related macular degeneration (AMD) and other low vision challenges

Retrieved on: 
Tuesday, June 1, 2021

Eyedaptic is the developer of game-changing eyewear, designed by retina specialists and low vision optometrists who understand the challenges millions of Americans with low vision and AMD face each day.

Key Points: 
  • Eyedaptic is the developer of game-changing eyewear, designed by retina specialists and low vision optometrists who understand the challenges millions of Americans with low vision and AMD face each day.
  • "EYE3 is a unique wearable device which contains simulated natural vision software, embedded in stylish eyewear, which augments the users' central field of vision.
  • "We are very excited about this premier version of Eyedaptic glasses," says Vispero Senior Vice President, Sales and Marketing, Jim McDonnell.
  • Eyedaptic is a privately held company that develops visual aid software, enabled by augmented reality hardware, for macular degeneration and other retinal diseases.

Insights on the Retinal Implants Global Market to 2027 - Featuring Abbott Vascular, Bionic Eye Technologies & Bionic Vision Australia Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 28, 2021

The "Retinal Implants - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Implants - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Implantable Miniature Telescope, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$41.8 Million by the end of the analysis period.
  • In the global Retina Implant Alpha AMS segment, USA, Canada, Japan, China and Europe will drive the 8.9% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.4 Million by the year 2027.

OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy

Retrieved on: 
Monday, May 3, 2021

OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).

Key Points: 
  • OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
  • Additionally, among the newly reported data, it was notable that Cohort 4 patients reported improvements in a majority of the vision parameters measured by a validated quality of life questionnaire.
  • The magnitude of these improvements was higher overall in Cohort 4 than in Cohorts 1 through 3, which is consistent with the larger clinical benefit observed among those patients.
  • Such statements include, but are not limited to, statements relating to the expected clinical outcomes of treatment with OpRegen in dry AMD patients with GA.

Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments

Retrieved on: 
Monday, April 19, 2021

b'BEDFORD, Texas, April 19, 2021 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced an expansion of its Clinical Advisory Board with the appointment of four new members.\n"We are honored to have such distinguished clinical experts in retinal disorders join us as advisers.

Key Points: 
  • b'BEDFORD, Texas, April 19, 2021 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced an expansion of its Clinical Advisory Board with the appointment of four new members.\n"We are honored to have such distinguished clinical experts in retinal disorders join us as advisers.
  • ; Vittorio Porciatti, DSc; Weldon Wright, M.D.
  • Nanoscope utilizes an ambient light-sensitive MCO molecule to re-sensitize the retina toward ambient light level.
  • The company\'s pipeline includes optogenetics based retinal regeneration therapy for vision restoration in patients with RP, Stargardt disease, and dry/end-stage wet age-related macular degeneration (AMD).

Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar

Retrieved on: 
Tuesday, March 2, 2021

COLUMBIA, Md., March 2, 2021 /PRNewswire/ --The Foundation Fighting Blindness, the world's leading private funding source for retinal degenerative disease research, will host an online continuing medical education (CME and COPE) course on Monday, April 5, 2021, at 7:00 p.m. Eastern Time.

Key Points: 
  • COLUMBIA, Md., March 2, 2021 /PRNewswire/ --The Foundation Fighting Blindness, the world's leading private funding source for retinal degenerative disease research, will host an online continuing medical education (CME and COPE) course on Monday, April 5, 2021, at 7:00 p.m. Eastern Time.
  • The studies provide hope for patients and the opportunity for them to participate in the research.
  • The continuing education course will enable eye care professionals to:
    Discusswhy it is essential for patients with inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and AMD to know about clinical research.
  • "He brings tremendous passion and enthusiasm to his role as a clinical researcher and retinal physician for retinal degeneration patients."

Global Retinal Implants Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 4, 2020

North America is expected to generate the highest revenue in the global retinal implant market over the forecast period.

Key Points: 
  • North America is expected to generate the highest revenue in the global retinal implant market over the forecast period.
  • High prevalence of degenerative conditions and technological advancements may drive growth of the North America retinal implants market over the forecast period.
  • Retinal implants are manufactured by few companies currently and only four types of implants have been approved by the US FDA.
  • Added to that, the favourable reimbursement facility for the retinal implant is acting as a driver for the growth of this market in this region.

Pixium Vision Hosting Key Opinion Leader Webinar on the Prima System for Atrophic Dry Age-related Macular Degeneration (dry-AMD)

Retrieved on: 
Friday, October 16, 2020

Pixium Vision's management team will give an update on their Prima Bionic Vision System.

Key Points: 
  • Pixium Vision's management team will give an update on their Prima Bionic Vision System.
  • Dr. Sahel was a co-founder of Fovea Pharmaceuticals, StreetLab, GenSight Biologics, Pixium Vision, Sparing Vision.
  • Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturized wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age- Related Macular Degeneration (AMD).
  • Pixium Vision has been qualified as an Innovative Company by Bpifrance
    This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business.